The only once-daily oral preventive CGRP receptor antagonist1

Turn on quick and continous migraine preventive power with QULIPTA

The only once-daily oral preventive CGRP receptor antagonist1

Turn on quick and continuous migraine preventive power with QULIPTA

Across a 12-week clinical trial (QULIPTA 60 mg)*:

Month Icon

Significant 54% reduction
in monthly mean migraine days vs 33% for placebo1,2

Similar results were seen in the Phase 2b/3 dose-finding study

Patient Icon

Over 60% of patients
cut their migraine days by at least half vs 29% for placebo1

Reduction Icon

With the majority of impact
observed within Weeks 1-41,3

*Data from the Phase 3 ADVANCE trial.

Month Icon

Significant 54% reduction in monthly mean migraine days vs 33% for placebo1,2

Similar results were seen in the Phase 2b/3 dose-finding study

Reduction Icon

With the majority of impact observed within Weeks 1-41,3

Patient Icon

Over 60% of patients cut their migraine days by at least half vs 29% for placebo1

*Data from the Phase 3 ADVANCE trial.